
|Videos|April 14, 2023
How PSA Has Impacted the Use of ADT in Prostate Cancer
Tia Higano, MD, FACP, provides a historical perspective on prostate cancer the use of androgen-deprivation therapy (ADT) and on prostate-specific antigen (PSA) in diagnosis and monitoring.
Advertisement
January 2023 AbbVie Inc. Company Confidential
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Initial prostate cancer presentation, family history linked to survival in mCRPC
2
Nicole L. Miller, MD, FACS, on persistent LUTS after BPH treatment
3
Datopotamab deruxtecan enters phase 3 trial in high-risk muscle-invasive urothelial cancer
4
AI system links surgical gestures with postoperative outcomes
5














